Inhibition of mTOR in carcinoid tumors

Targeted Oncology

Volumn 7, Issue 3, 2012, Pages 189-195

  Grozinsky Glasberg, Simona ^a   Pavel, Marianne ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carcinoid; Everolimus; MTOR; Neuroendocrine tumor; Temsirolimus

Indexed keywords

BEVACIZUMAB; CIXUTUMUMAB; ERLOTINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PASIREOTIDE; PLACEBO; RIDAFOROLIMUS; SOMATOSTATIN DERIVATIVE; SORAFENIB; TEMSIROLIMUS;

ADVANCED CANCER; ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER THERAPY; CARCINOGENESIS; CARCINOID; CARCINOID SYNDROME; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FATIGUE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; OPEN STUDY; PANCREAS ISLET CELL CARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; TUMOR DIFFERENTIATION; TUMOR REGRESSION; UPPER RESPIRATORY TRACT INFECTION;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEUROENDOCRINE TUMORS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; SOMATOSTATIN; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84872278627     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0225-x     Document Type: Review

References (30)

1. Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31(2): 169-188
2. Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28): 4656-4663
3. Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2): 157-176
4. Eriksson B, Kloppel G, Krenning E et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87(1): 8-19
5. Brizzi MP, Berruti A, Ferrero A et al (2009) Continuous 5- fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer 9: 388
6. Maire F, Hammel P, Faivre S et al (2009) Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology 90(1): 67-72
7. Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing lowgrade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59(5): 637-642
8. Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17(2): 150-157
9. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4): 257-262
10. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1): 9-22
11. Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3(4): 371-377
12. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5): 335-348
13. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5 (8): 671-688
14. Houghton PJ, Morton CL, Kolb EA et al (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4): 799-805
15. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449-456
16. Okamoto I, Doi T, Ohtsu A et al (2010) Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40(1): 17-23
17. Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28(1): 69-76
18. Abraham RT, Gibbons JJ (2007) The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13(11): 3109-3114
19. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50): 7455-7464
20. Wang L, Ignat A, Axiotis CA (2002) Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 10(2): 139-146
21. Zitzmann K, De Toni EN, Brand S et al (2007) The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85(1): 54-60
22. Grozinsky-Glasberg S, Franchi G, Teng M et al (2008) Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuroendocrine tumour cell Line. Neuroendocrinology 87(3): 168-181
23. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM (2011) Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 117 (18): 4141-4154
24. Duran I, Kortmansky J, Singh D et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9): 1148-1154, Epub 2006 Oct 10
25. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6): 514-523
26. Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26(26): 4311-4318
27. Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT- 2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808): 2005-2012
28. Yao J, Hainsworth JD,Wolin EM et al (2012) Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). J Clin Oncol 30 (suppl 4; abstr 157)
29. Pavel M, Wiedenmann B, Capdevila J, Reed N, Valle JW, Caglio S, May C, Comis S, Castellana R, de Herder WW, Metzner C, Salazar R, Hörsch D, Öberg K (2012) RAMSETE: a single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuroendocrine tumours in Europe. J Clin Oncol 30 (suppl; abstr 4122)
30. Bushnell D, O'Dorisio TM, O'Dorisio MS et al (2010) 90Yedotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28(10): 1652-1659